Brought to you by 
BioCryst, Presidio to merge and focus on HCV and HAE programs; terminated
30 Nov 2012
Executive Summary
BioCryst Pharmaceuticals Inc. is buying privately held infectious disease-focused firm Presidio Pharmaceuticals Inc. in a stock swap. BioCryst is issuing Presidio shareholders 24.5mm common shares at $4.36 each, valuing the transaction at $106.8mm.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Withdrawn
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Includes Contract
- Intra-Biotech Deal
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
BioCryst, Presidio to merge and focus on HCV and HAE programs; terminated
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice